Acute-Phase Treatment

Key points
- General Issues Defining Objectives In selecting among acute-phase treatments, clinicians find that it is often useful to define the treatment objective(s) with patients.
- Determining When Formal Treatment Is Indicated Milder, less chronic, less recurrent forms of major depressive disorder respond, and in some cases symptomatic remission occurs, without specific medication or even formal psychotherapeutic intervention.
- Patients with depressive disorder who have higher rates of response to nonspecific treatment generally have illnesses with less chronicity (fewer episodes, complete interepisode recoveries), fewer psychiatric and general medical comorbid conditions, and less severe symptom levels at initial evaluation.
- Note that for less severe, less complex depression, there is little evidence that the combination of medication and formal psychotherapy produces symptom relief greater than that obtained with either treatment alone.
General Issues
Defining Objectives
In selecting among acute-phase treatments, clinicians find that it is often useful to define the treatment objective(s) with patients. If they understand what to expect, they can better collaborate in determining whether or not the objectives are met. In addition, with defined objectives, clinicians can more clearly decide if the initial treatment choices were appropriate (i.e., were the objectives met?). As a result, subsequent strategic revisions in the treatment plan, such as switching or augmenting treatments or extending the treatment period, can be implemented in a timely fashion. The initial objectives of acute-phase treatment are symptom remission and restoration of psychosocial functioning, although the latter occurs sometimes weeks or even months after symptom improvement.
Determining When Formal Treatment Is Indicated
Milder, less chronic, less recurrent forms of major depressive disorder respond, and in some cases symptomatic remission occurs, without specific medication or even formal psychotherapeutic intervention. For example, Elkin et al. (1989) found that pill-placebo plus clinical management had an efficacy equal to that of imipramine in depressed outpatients with Hamilton Rating Scale for Depression scores less than 19, although the remission rates in the pill-placebo/clinical management cell tended to be somewhat lower than those in the medication cell. However, placebo responders fared poorly during the subsequent 18-month naturalistic follow-up study found that 50% of placebo responders largely maintained the response.
Patients with depressive disorder who have higher rates of response to nonspecific treatment generally have illnesses with less chronicity (fewer episodes, complete interepisode recoveries), fewer psychiatric and general medical comorbid conditions, and less severe symptom levels at initial evaluation. For these less severely ill patients whose illnesses are less chronic and complex, an extended evaluation of several weeks may be useful to assess the need for formal treatment. However, response to extended evaluation does not predict a uniformly good outcome over the longer course, so postresponse follow-up visits are desirable.
Selecting the Initial Treatment
Factors affecting the selection of the initial treatment include the chronicity of the depression, whether residual symptoms continue between full episodes, the history of recurrences (which predicts the likelihood of future recurrences), family history of illness, symptom severity, associated comorbid general medical or other psychiatric conditions, prior treatment responses to other acute-phase treatments, and patient preference. Note that for less severe, less complex depression, there is little evidence that the combination of medication and formal psychotherapy produces symptom relief greater than that obtained with either treatment alone. In general, the less severe, less chronic, and less complex the depression, the greater the role for patient preference, because evidence on which to base the selection between psychotherapy (time-limited, targeted type) and medication is largely absent.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsFragile X study offers hope of new autism treatment
People affected by a common inherited form of autism could be helped by a drug that is being tested as a treatment for cancer. Researchers who have identified a chemical pathway that goes awry in the brains of Fragile X…
29 November 2014
NewsFor prescription drug addiction treatment, buprenorphine maintenance trumps detoxification
For treating patients with prescription opioid dependence in primary care, buprenorphine maintenance therapy is superior to detoxification, according to a new study by Yale School of Medicine researchers published in…
21 October 2014
NewsState policies can influence access to heroin treatment, study finds
State policies can influence the number of physicians licensed to prescribe buprenorphine, a drug that can treat addiction to heroin and other opioids in outpatient settings, according to a new RAND Corporation study.…






